Systemic low-dose isotretinoin maintains remission status in epidermodysplasia verruciformis

doi:10.1111/j.1468-3083.2007.02394.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Journal of the European Academy of Dermatology and Venereology

Volume 22 Issue 4, Pages 523 - 525

Published Online: 12 Jul 2007

Published on behalf of the European Academy of Dermatology and Venereology

Go to Society Site

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 126K) | Related Articles | Citation Tracking

LETTERS TO THE EDITOR

Systemic low-dose isotretinoin maintains remission status in epidermodysplasia verruciformis

E Rallis†*, G Papatheodorou‡, E Bimpakis†, D Butanska§, P Menounos‡, P Papadakis†

†Department of Dermatology, ‡Clinical Research Unit and §Department of Pathology, Army General Hospital, Athens, Greece,

*Corresponding author, 11 Pafsaniou Street, Athens, Greece, GR-11635, tel./fax +30 2107244008; E-mail: efrall@otenet.gr

The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

DOI: 10.1111/j.1468-3083.2007.02394.x